Robert Chess - Net Worth and Insider Trading
Robert Chess Net Worth
The estimated net worth of Robert Chess is at least $7 Million dollars as of 2026-07-22. Robert Chess is the Director of Twist Bioscience Corp and owns about 63,612 shares of Twist Bioscience Corp (TWST) stock worth over $6 Million. Robert Chess is also the Director of Nektar Therapeutics and owns about 17,298 shares of Nektar Therapeutics (NKTR) stock worth over $1 Million. Details can be seen in Robert Chess's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert Chess has not made any transactions after 2026-03-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Robert Chess
Robert Chess Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Robert Chess owns 2 companies in total, including Nektar Therapeutics (NKTR) , and Twist Bioscience Corp (TWST) .
Click here to see the complete history of Robert Chess’s form 4 insider trades.
Insider Ownership Summary of Robert Chess
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| NKTR | Nektar Therapeutics | 2024-06-14 | director |
| TWST | Twist Bioscience Corp | 2026-03-17 | director |
Robert Chess Latest Holdings Summary
Robert Chess currently owns a total of 2 stocks. Among these stocks, Robert Chess owns 63,612 shares of Twist Bioscience Corp (TWST) as of March 17, 2026, with a value of $6 Million and a weighting of 83.48%. Robert Chess also owns 17,298 shares of Nektar Therapeutics (NKTR) as of June 14, 2024, with a value of $1 Million and a weighting of 16.52%.
Latest Holdings of Robert Chess
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TWST | Twist Bioscience Corp | 2026-03-17 | 63,612 | 95.08 | 6,047,911 |
| NKTR | Nektar Therapeutics | 2024-06-14 | 17,298 | 69.17 | 1,196,503 |
Holding Weightings of Robert Chess
Robert Chess Form 4 Trading Tracker
According to the SEC Form 4 filings, Robert Chess has made a total of 12 transactions in Twist Bioscience Corp (TWST) over the past 5 years, including 0 buys and 12 sells. The most-recent trade in Twist Bioscience Corp is the sale of 10,000 shares on March 17, 2026, which brought Robert Chess around $470,000.
According to the SEC Form 4 filings, Robert Chess has made a total of 5 transactions in Nektar Therapeutics (NKTR) over the past 5 years, including 0 buys and 5 sells. The most-recent trade in Nektar Therapeutics is the sale of 1,300 shares on June 14, 2024, which brought Robert Chess around $23,400.
Insider Trading History of Robert Chess
* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.
- 1
Robert Chess Trading Performance
Robert Chess Ownership Network
Ownership Network List of Robert Chess
Ownership Network Relation of Robert Chess
Robert Chess Owned Company Details
What does Nektar Therapeutics do?
Who are the key executives at Nektar Therapeutics?
Robert Chess is the director of Nektar Therapeutics. Other key executives at Nektar Therapeutics include Chief R&D Officer Jonathan Zalevsky , director & President & CEO Howard W Robin , and Interim CFO Linda M Rubinstein .
Nektar Therapeutics (NKTR) Insider Trades Summary
Over the past 18 months, Robert Chess made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 40,565 shares made by Jonathan Zalevsky , a net sale of 91,627 shares made by Howard W Robin , and a net sale of 22,342 shares made by Mark Andrew Wilson .
In summary, during the past 3 months, insiders sold 31,862 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 31,862 shares. During the past 18 months, 71,439 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 71,439 shares.
Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nektar Therapeutics Insider Transactions
Robert Chess Mailing Address
Above is the net worth, insider trading, and ownership report for Robert Chess. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Robert Chess's mailing address is: South San Francisco Ca 94080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
